Rainbows and Unicorns: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Became A Lot More Optimistic

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Following the upgrade, the consensus from twelve analysts covering NewAmsterdam Pharma is for revenues of US$32m in 2025, implying a painful 51% decline in sales compared to the last 12 months. Losses are forecast to narrow 8.5% to US$1.35 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$19m and losses of US$1.81 per share in 2025. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for NewAmsterdam Pharma

There was no major change to the consensus price target of €34.51, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic NewAmsterdam Pharma analyst has a price target of €38.64 per share, while the most pessimistic values it at €23.17. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. Over the past three years, revenues have declined around 37% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 76% decline in revenue until the end of 2025. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 20% per year. So while a broad number of companies are forecast to grow, unfortunately NewAmsterdam Pharma is expected to see its sales affected worse than other companies in the industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around NewAmsterdam Pharma's prospects. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to this year's earnings expectations, it might be time to take another look at NewAmsterdam Pharma.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple NewAmsterdam Pharma analysts - going out to 2027, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.